Clinical Trials
- Thyroid and Other Endocrine Cancers
A Phase III Study of Targeted Therapy vs. Chemotherapy in Patients with Thyroid Cancer
- Ages18 years and older
- GenderBoth
- Lung Cancer
Targeted Treatment for Advanced Non-Small Cell Lung Cancer that has a MET Exon 14 Skipping Gene Change (An Expanded Lung-MAP Treatment Trial)
- Phase 1 Cancers
First-In-Human, Open-Label, Dose Escalation Trial With Expansion Cohorts to Evaluate the Safety and Preliminary Efficacy of GEN1055 as Monotherapy and as Combination Therapy in Subjects With Malignant Solid Tumors
- Breast Cancer
Use of DiviTum -TKa as a biomarker assay for CDK4/6 inhibitor medication compliance and drug-drug interactions assessment and intervention in HR-positive metastatic breast cancer patients
- Phase 1 Cancers
A Multicenter, Open-Label, Phase 1a/b First-in-Human Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of BG-C477 in Patients With Selected Advanced Solid Tumors
- Phase 1 Cancers
A Phase 1a/b, Open-label, Multicenter Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of BG-C137, an Antibody-Drug Conjugate Targeting FGFR2b, in Patients With Advanced Solid Tumors
- Phase 1 Cancers
A Phase 1/2a, Open-Label, Safety, Pharmacokinetic, And Preliminary Efficacy Study Of Oral ATRN-119 In Patients With Advanced Solid Tumors
- Phase 1 Cancers
A Phase 1a Open-Label, Dose-Escalation, and a Phase 2 Study to Investigate the Safety, PK, PD, and Clinical Activity of ST-067 Administered Subcutaneously as Monotherapy in Patients With Relapsed or Refractory Solid Tumors
- Phase 1 Cancers
First-in-Human Study of STX-478, a Mutant-Selective PI3Kα Inhibitor as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumor
- Phase 1 Cancers
A Phase I Dose-Escalation and Dose-Expansion Study Evaluating the Safety, Pharmacokinetics, and Activity of GDC-6036 in Patients With Advanced or Metastatic Solid Tumors With a KRAS G12C Mutation